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Abstract
Background: Developing chemotherapy resistant cell lines can help to identify markers of resistance. Instead of using a
panel of highly heterogeneous cell lines, we assumed that truly robust and convergent pattern of resistance can be
identified in multiple parallel engineered derivatives of only a few parental cell lines.
Methods: Parallel cell populations were initiated for two breast cancer cell lines (MDA-MB-231 and MCF-7) and these were
treated independently for 18 months with doxorubicin or paclitaxel. IC50 values against 4 chemotherapy agents were
determined to measure cross-resistance. Chromosomal instability and karyotypic changes were determined by
cytogenetics. TaqMan RT-PCR measurements were performed for resistance-candidate genes. Pgp activity was measured
by FACS.
Results: All together 16 doxorubicin- and 13 paclitaxel-treated cell lines were developed showing 2–46 fold and 3–28 fold
increase in resistance, respectively. The RT-PCR and FACS analyses confirmed changes in tubulin isofom composition, TOP2A
and MVP expression and activity of transport pumps (ABCB1, ABCG2). Cytogenetics showed less chromosomes but more
structural aberrations in the resistant cells.
Conclusion: We surpassed previous studies by parallel developing a massive number of cell lines to investigate
chemoresistance. While the heterogeneity caused evolution of multiple resistant clones with different resistance
characteristics, the activation of only a few mechanisms were sufficient in one cell line to achieve resistance.
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Introduction
Breast cancer chemotherapy resistance is a complex multifac-
torial problem, where several pathways may act simultaneously
and influence each other leading to failure of systemic treatment
[1]. Doxorubicin and paclitaxel are used in recurrent or metastatic
breast cancer as a single agent or in combination (http://www.
nccn.org).
A principal mechanism of action of anthracyclines is their
ability to intercalate into DNA. DNA-bound anthracycline binds
DNA topoisomerase II, inducing DNA cleavage in an ATP-
dependent manner [2]. Anthracycline resistance might be
mediated through overexpression of P-glycoprotein [3,4,5], lung
resistance protein [6] and multidrug-resistance proteins [7,8],
proteasome subunits [9], increases in antioxidant defenses [10],
alterations in apoptotic signaling and TOP2 activity [5,11,12].
Most recently, over-expression of genes in the chromosomal
region 8q22 have been shown to be associated with anthracycline
resistance. One of those genes, LAPTM4B, sequesters anthracy-
clines away from the nucleus, the location of their therapeutic
action [13]. Taxanes act on the microtubuli and resistance
against them might be mediated through expression changes and
mutations in ABC transporters like MDR1 [1,14,15], beta-
tubulin isoforms [16,17], tubulin mutations [18] and mictotubule-
associated protein tau [19]. Identification of resistance mecha-
nisms holds the potential of developing biomarkers that can
predict disease outcome following treatment with specific
chemotherapeutic agents.
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There are several alternative strategies to develop chemother-
apy response predictors, none of them being ideal, each having its
own advantages and disadvantages. Genome scale molecular
profiling, such as microarray analysis of tumor biopsies has the
potential of most faithfully characterizing the molecular changes
associated with response to therapy in the primary tumors [20,21].
However, due to the large number of variables (tens of thousands
of measured genes) relative to the limited number of patients in
those cohorts (a few hundred at most) such studies are prone to
overfitting [22]. A possible way to circumvent this issue is
identifying the potentially relevant biomarkers or mechanisms
from either prior biological knowledge coupled with bioinfor-
matics analysis [23], or from appropriate model systems such as
cancer cell lines. A breast cancer specific follow up on the initially
optimistic studies using cancer cell lines [24,25], however, failed to
identify clinically validated biomarkers. For example, a clinical
evaluation of chemotherapy response predictors developed from
breast cancer cell lines was performed recently [26]. In this study,
nineteen cell lines were used to derive predictors of response to
paclitaxel (T), 5-fluorouracil (F), doxorubicin (A) and cyclophos-
phamide (C). Then, the signatures were used to classify over
hundred patients who received preoperative TFAC chemothera-
py. However, there was no significant correlation between
response and predicted response for either individual or for
combined predictors.
An apparent problem with this and earlier studies was the use of
a panel of highly heterogeneous cell lines for the identification of
the predictors. Developing resistant cell lines to a given agent and
then comparing the resistant and the sensitive parent cell line may
circumvent this problem. For example MET inhibitors were
recently investigated by Qi et al [27] by the comparison of a
gastric carcinoma cell line and three resistant sub–cell lines. They
Figure 1. Overview of the generation of cell lines. The original cell lines were split and new cell lines were generated parallel by treatment with
gradually increasing concentration of doxorubicin or paclitaxel (detailed description of the treatment protocol is in the Methods section).
doi:10.1371/journal.pone.0030804.g001
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found at least two mechanisms of resistance that arose simulta-
neously and they also observed the capability of a single cancer cell
to develop multiple, distinct resistance mechanisms simultaneous-
ly. Similar results were observed in lung cancer patients resistant to
EGFR inhibitors [28,29].
In the present study we went one step further in the simulation
of the evolution of chemotherapy resistance development in a cell
culture by significantly increasing the number of parallel
developed cell lines. We assumed that truly robust and relevant
resistance mechanisms will emerge in multiple cell lines and a
clinically relevant convergent pattern of resistance can be
identified. Twenty-nine subpopulations of two breast cancer cell
lines were separated and treated with increasing concentrations of
doxorubicin and paclitaxel for 18 months. These cells were then
investigated to explore whether known resistance mechanisms
consistently emerge and therefore the same strategy could be used
to identify novel mechanisms as well.
Materials and Methods
Cell culture maintenance
The human breast cancer cell lines MCF-7 and MDA-MB-231
were obtained from ATCC, they were cultured in Leibovitz L-15
medium (Invitrogen) supplemented with 10% fetal calf serum
(Invitrogen), 2.5 mg/l transferrin, 1.1 g/l NaHCO3, 1% minimal
essential vitamins, and 20 000 kIE/l trasylol in a humidified
atmosphere containing 5% CO2 at 37uC.
Development of resistant cell populations
Ten sub-populations of each cell line for each of the two drugs
were separated. The new cell lines were generated parallel by
treatment with gradually increasing concentration of doxorubicin
(EBEWE Pharma, Unterach, Austria) or paclitaxel (Sigma-
Aldrich, Steinheim, Germany). After each week, the confluence
was assessed: for cells lines with confluence below 50%, the
Table 1. Cross-resistance against doxorubicin (DOX), paclitaxel (PAX), cisplatin (CISP) and 5-fluorouracil (5-FU) in the generated
breast cancer cell lines.
Cell line Treatment IC50 (PAX) IC50 (DOX) IC50 (CISP) IC50 (5-FU)
MCF-7 Vehicle 2.33 2 2.55 0.07
MDA-MB-231 Vehicle 2.05 2.12 2.46 0.09
MDA-MB-231-R1 Doxorubicin 7.06 8.06 9.13 0.03
MDA-MB-231-R4 Doxorubicin 8.34 8.11 2.75 0.05
MDA-MB-231-R5 Doxorubicin 6.06 7.79 2.98 0.09
MDA-MB-231-R8 Doxorubicin 5.83 9 2.39 0.3
MDA-MB-231-R9 Doxorubicin 6.93 98.45 3.3 0.09
MDA-MB-231-R10 Doxorubicin 6.55 62.44 2.46 0.06
MDA-MB-231-R11 Paclitaxel 49.66 5.9 3.46 0.07
MDA-MB-231-R12 Paclitaxel 9.32 3.46 6.82 2.15
MDA-MB-231-R13 Paclitaxel 7.89 6.4 2.95 45.04
MDA-MB-231-R15 Paclitaxel 5.34 8.38 5.51 49.9
MDA-MB-231-R16 Paclitaxel 18.54 4.82 0.84 3.2
MDA-MB-231-R17 Paclitaxel 8.49 4.1 5.96 0.01
MDA-MB-231-R18 Paclitaxel 6.35 2.94 4.48 0.09
MDA-MB-231-R19 Paclitaxel 58.18 1.98 1.07 0.07
MDA-MB-231-R20 Paclitaxel 6.69 7.75 2.1 0.1
MCF-7-R1 Doxorubicin 6.88 4.46 3.14 0.4
MCF-7-R2 Doxorubicin 5.22 6.79 6.63 57.27
MCF-7-R3 Doxorubicin 4.24 4.3 3.81 0.07
MCF-7-R4 Doxorubicin 5.16 8.52 3.02 0.06
MCF-7-R5 Doxorubicin 0.7 4.19 3.45 1.61
MCF-7-R6 Doxorubicin 6.61 24.13 1.3 0.04
MCF-7-R7 Doxorubicin 6.65 9.42 4.34 0.09
MCF-7-R8 Doxorubicin 2.41 19.26 2.11 0.05
MCF-7-R9 Doxorubicin 5.34 6.28 3.1 0.05
MCF-7-R10 Doxorubicin 6.31 15.21 0.15 0.04
MCF-7-R12 Paclitaxel 6.61 4.74 6.02 0.04
MCF-7-R13 Paclitaxel 5.86 7.91 0.44 58.12
MCF-7-R14 Paclitaxel 7.48 26.94 1.16 3.95
MCF-7-R20 Paclitaxel 9.93 57.39 4.35 0.23
Although some cell lines exhibited highly marked resistance against other agents, no significant correlation between the relative resistance levels was observed. IC50:
mg/ml.
doi:10.1371/journal.pone.0030804.t001
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treatment was stopped, for confluence between 50–70%, the
treatment was maintained and for those with a confluence over
70% a portion of the cells was frozen. After 3 weeks of growth at a
specific dose of treatment, the concentration was increased. The
increase was in 10 fold increments until we reached 0.16 the
clinical dose, then 0.36 and 0.66 followed. Before drug
concentration increase an MTT cell proliferation assay (Cell
Proliferation Kit I (MTT) Roche, IN, USA) was performed to
monitor sensitivity of the resistant cell lines. Additionally, vehicle-
treated parental cell lines were kept in culture for the duration of
the study and these were used as control cell lines.
Measurement of cross-resistance
Cross-resistance measurements were performed on the parental
and the resistant cell lines. IC50 values were determined for
cisplatin (Sigma-Aldrich, Steinheim, Germany), doxorubicin,
paclitaxel and 5-fluorouracil (Sigma-Aldrich, Steinheim, Ger-
many) using the MTT Cell Proliferation Kit (Roche, Mannheim,
Germany) and GraphPad Prism software.
TaqMan RT-PCR measurements
TaqMan real-time PCR was used to measure the expression of
selected genes using an Applied Biosystems Micro Fluidic Card
System in 31 samples (27 resistant sub-lines and both parental cell
lines in duplicates). The measurements were performed using an
ABI PRISMH 7900HT Sequence Detection System as described
in the products User Guide (http:// www.appliedbiosystems.com,
CA, USA). The genes were selected based on a literature search, to
include genes correlated to doxorubicin and paclitaxel resistance,
breast cancer hormone receptors and survival associated genes.
The complete list of genes and TaqMan IDs are listed in Table
S1. For data analysis the SDS 2.2 software was used. The
extracted delta Ct values were normalized to the average of 3
different housepeeking genes (18S, HPRT1 and RPLP0). Spear-
man rank correlation was computed to compare the expression for
the genes and the resistance against doxorubicin and paclitaxel.
Step-up multiple testing correction was performed [30] and
statistical significance was set at p= 0.05. For the visualization of
the results, hierarchical clustering was performed using the
Genesis software.
Flow cytometric analysis
The ability of the cells to carry out of Pgp-mediated efflux was
assessed by using the Pgp substrate rhodamine 123. Cells were
seeded in 6-well plates at a density of 56105 cells and allowed to
attach overnight. Doxorubicin or paclitaxel (for the resistant cell
lines, respectively) were added to the cells and incubated for 0.5 h,
then rhodamine 123 (10 mM) was added to the cells and after
incubation the cells were collected and washed with fresh medium
and resuspended in normal growth medium without doxorubicin/
paclitaxel or rhodamine 123. Then the cells were centrifuged and
washed in ice-cold PBS. At last, the cells were resuspended in 1 ml
PBS and analyzed by flow cytometry. Fluorescence was measured
from 104 cells and cell-count was plotted against rhodamine
intensity.
Conventional cytogenetics
After the end of the development, treated and vehicle-treated
cell lines were cultured for 3–5 days. When the monolayer cultures
showed ,80% confluence, they were incubated overnight with
0,02–0,06 mg/ml final concentration of Colcemid. After detaching
the cells with 16 trypsin/EDTA, chromosomal preparations were
made according to standard techniques that used 0,067 M KCl as
hypotonic treatment and fixation in methanol/acetic acid.
Chromosome analysis was performed on metaphase cells G-
banded with trypsin and Wright Giemsa stain. Ten metaphases
were evaluated for each sample with an Axioskop 2 Mot Plus
microscope (Carl Zeiss GmbH, Germany) and Cytovision 3.6 or
Mac Ktype 5.6 computer analysis system for karyotyping
(Scientific Systems, UK). Karyotypes were described according
to the International System for Human Cytogenetic Nomenclature
(ISCN 2009).
Chromosomal instability
Chromosomal instability (CIN) was measured by counting the
average number of variations of chromosomes 3, 17 and 21 in ten
different metaphases. Then, the Shannon Diversity Index (H) was
computed using the formula [31]:
H~{
X
i
pi ln(pi)
Figure 2. Circos plots showing the relative cross-resistance for MCF-7 derivatives (A,) and MDA-MB-231 derivatives (B,) against four
chemotherapy agents. The ribbon thickness corresponds to the relative resistance. Yellow cell lines were treated with doxorubicin and orange cell
lines with paclitaxel. Note the high cross-resistance against 5-fluorouracil in three paclitaxel-treated and one doxorubicin-treated cell line. In contrast,
minimal cross-resistance against cisplatin can be observed. 5FU: 5-fluorouracil, CISP: cisplatin, DOX: doxorubicin, PAX: paclitaxel.
doi:10.1371/journal.pone.0030804.g002
Parallel Development of Chemoresistant Cell Lines
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e30804
where pi is the frequency of a given number of a chromosome (i) in
the cell lines. Thus, H was used to estimate the degree of
numerical chromosomal heterogeneity within each of the
developed resistant cell lines. Cell lines having an index at least
2.1 were designated as CIN positive (CIN+) tumors and remaining
cell lines were designated as CIN negative (CIN2) tumors.
Results
Development of resistant cell populations
At the end we obtained 29 resistant cell lines as a result of 18
months of treatment. There are 10 doxorubicin and 4 paclitaxel
resistant MCF-7 cell lines, 6 doxorubicin and 9 paclitaxel resistant
MDA-MB-231 cell lines. The relative resistance values compared
to the original cell lines show up to 46 (average: 18.5) fold
resistance against doxoxubicin and up to 28 (average: 15.4) fold
resistance against paclitaxel. No cell line exhibited less than two-
fold increase in the IC50 values. Figure 1. illustrates an overview
of the process.
Cross-resistance to four anticancer agents
We determined the level of cross-resistance by determining the
IC50 values against four widely used agents in the treatment of
breast cancer (doxorubicin, paclitaxel, cisplatin and 5-fluoroura-
cil). Although some of the cell lines exhibited significantly
increased resistance against other agents as well, no significant
correlation between the relative resistance levels was observed.
The smallest relative resistance developed against cisplatin. Four
cell lines (three of them treated with paclitaxel and one treated
with doxorubicin) developed dramatic resistance against 5-
fluorouracil. Table 1. and Figure 2. shows the cross-resistance
properties of all cell lines against all used chemotherapy agents.
RT-PCR of pre-selected genes
Gene expression of a set of selected genes was measured by
TaqMan real-time PCR. The gene expression levels were
correlated to the IC50 values using Spearman’s rank correlation
test. In the doxorubicin resistant cell lines the expression of
TOP2A (p= 0.003) and two tubulin isoforms (TUBB2C,
Figure 3. Hierarchical clustering image of the samples using the RT-PCR measured genes in both doxorubicin- and paclitaxel-
resistant cell lines. Red and green: up- and down- regulated as compared to the mean of all experiments. The white dots represent the sample
with the highest absolute expression. Overall only a few mechanisms are activated in one cell line to achieve resistance.
doi:10.1371/journal.pone.0030804.g003
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p= 0.003; TUBB3, p= 0.006) was correlated to the level of
resistance significantly. In the paclitaxel resistant cell lines, the
expression of MVP (p= 0.009), of four tubulin isoforms (TUBA1C,
p= 0.003; TUBB2A, p= 0.009, TUBB4, p= 0.005) and of MAP4
(p = 0.001) correlated to resistance. ABCB1 reached a p value of
0.03 and 0.07 in the doxorubicin- and pacalitaxel-treated cell lines,
respectively but these were not significant after multiple testing
corrections. Hierarchical cluster visualizing the results is presented
on Figure 3. This figure also shows the cell line with the highest
absolute expression for the selected gene. Generally only a few
mechanisms are activated in one cell line to achieve resistance.
Rhodamine 123 efflux demonstrates different Pgp
function in the resistant cell lines
The ability to export drugs via Pgp-activity was assessed by
FACS using the Pgp substrate rhodamine 123. The originally
paclitaxel-resistant MCF-7-R20 cell lines showed the highest
cross-resistance against doxorubicin. The paclitaxel-resistant
MDA-MB-231-R19 showed the highest resistance against
paclitaxel and also showed rhodamine efflux. Two paclitaxel-
resistant cell lines (MCF-6-R5 and MCF-7-R7) showed also
increased resistance against doxorubicin and cisplatin. However,
a general correlation between rhodamine efflux and multidrug
resistance for other agents and other cell lines could not be
observed. The results of the FACS analysis for selected sets of cell
lines are shown in Figure 4.
Cytogenetics
Cytogenetics was performed on all cell lines derived from the
MDA-MB-231 cell line. The comparison of vehicle-treated and
parental cell lines did not show new structural abnormalities, but
the number of a few chromosomes (5, 13 and 17) changed in the
vehicle treated cells compared to the parental cells. Meanwhile,
there was a high number of genetic changes in the generated cell
lines. The new cell lines had 60–110 chromosomes, chromosomes
1, 17 and 21 had the most copies. Based on G-band staining, the
highest variability among the chromosomes were observed on
chromosomes 3, 7, 17, 20 and 21. Most stable chromosomes were
X, 10, 13 and 16. The most common gains were on chromosomes
15, 18 and 21. The most common deletions were 9p21 and 18q21.
Two of the cell lines (MDA-MB-231-R5 and MDA-MB-231-R11)
differed from the other cell lines by having a nearly tetraploid
modal chromosome number. The chromosomal changes and a
representative karyotypes are depicted in Figure 5. The main
difference between the parental and the developed cell lines is in
the lower number of chromosomes with higher number of new
type structural rearrangements in the derivative cell lines (see
Figure 5./D.).
Chromosomal instability
Statistical measures of diversity typically integrate both
number and abundance of chromosomes. The Shannon diversity
index is preferable to other diversity measures like the Simpson’s
Figure 4. Flow cytometric analysis of rhodamin 123 stained resistant and parental MDA-MB-231 and MCF7 cell lines. (black: parental
cell line, red: resistant cell line showing altered Pgp function, green: resistant cell line with normal Pgp function). A, MDA-MB-231-R19 (red), MDA-MB-
231-R11 (green); B, MDA-MB-231-R1 (red), MDA-MB-231-R8 (green); C, MCF7-R7 (red), MCF7-R2 (green); D, MCF7-R20 (red), MCF7-R12 (green).
Differences between the Pgp function of the resistant cell lines suggest, that alteration of the Pgp function can only explain the resistance in a few
cell lines.
doi:10.1371/journal.pone.0030804.g004
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index as it is not dominated by the most frequent chromosome
[32]. The average Shannon index across all cell lines was 2.03,
the parental MDA-MB-231 cell line had an index of 2.05.
Chromosomal instability was found in five cell lines (see
Figure 5./E.). The CIN+ cell lines had a higher average
cross-resistance as compared to the CIN- cell lines (for paclitaxel
7.1 vs. 6.7 mg/ml, cisplatin 4.2 vs. 3.5 mg/ml and 5-fluorouracil
10.1 vs. 5.1 mg/ml).
Discussion
Starting from two breast cancer cell lines, one estrogen receptor
positive and one estrogen receptor negative, using increasing
concentrations of paclitaxel and doxorubicin we parallel developed
29 cell lines to establish a model similar to the evolution of the
acquired drug resistance. We established a significantly higher
number of resistant cell lines compared to previous studies [28] in
the hope of achieving increased reliability and robustness.
Interestingly, at the end the cell lines proved to be highly
heterogeneous in the development of (multi) drug resistance and in
confirmed genetic alterations.
In our study we focused on two questions. First, whether the
multiple cell line-panel can re-identify previously clinically
validated predictors of chemotherapy resistance. Our results
suggest an affirmative answer and therefore validate the multiple
cell line panel as a promising tool for the identification of clinically
relevant biomarkers.
Second, we were interested to see how often we see multiple
drug resistance emerging when selected only with a single agent.
Of the 29 resistant cell lines, 25 displayed at least two-fold
increased resistance against another agent, 12 of the cell lines
developed over two-fold resistance against at least three agents
simultaneously, and two cell lines developed at least two-fold
resistance against all four agents. Therefore, while most cell lines
developed resistance to at least one more drug in addition to the
agent used for selection pressure, the emergence of a truly
multidrug resistance phenotype seems to be a relatively rare event.
This is in line with the clinical observations that tumors that
developed resistance to first line therapy are still often sensitive to
second or third line agents [33].
In previous studies [1,5] we confirmed the role of members of
the ATP-binding cassette family to be associated with MDR.
Our FACS analysis results confirmed the correlation between
ABCB1 expression and ABCB1 function, further supporting the
role of ABCB1 in drug resistance. However, when compared
across all the generated cell lines, members of the ABC
transporter family were not always correlated to the develop-
ment of resistance.
It is also notable that two genes selected for their previously
described association with taxane resistance (TUBB2C ad
TUBB3) were associated with doxorubicin resistance in our cell
line panel, but with the opposite trend, and MVP, selected for its
reported association with doxorubicin resistance, showed a
significant correlation with taxane resistance.
Figure 5. Complete overview of cytogenetic aberrations of the resistant derivatives of the MDA-MB-231 cell line. White background:
normal chromosomes, green background: chromosomes of the parental MDA-MB-231 cell lines, red background: chromosomal changes in the
resistant cell lines (A,). Position of the most important genes are marked by blue arrows. Representative karyotype of the MDA-MB-231-R18 cell line
(B,); ploidity (C,) and number of new structural aberrations (D,) on each chromosome across the parental (blue) and all resistant (red) cell lines.
Chromosomal instability (CIN) was measured computing the Shannon Diversity Index for chromosomes 3, 17 and 21 in ten different metaphases.
Threshold for chromosomal instability (CIN+) was set above 2.1 (E,).
doi:10.1371/journal.pone.0030804.g005
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Our study shows that the heterogeneity results in the evolution
of multiple drug resistant tumor cell populations with different
geno- and phenotype. The evolution of multiple resistant cell
populations may require developing new treatment strategies to
prevent or overcome resistance. Multiple samples from the tumor
may give better insight into the clonal composition of the tumor.
However it is impractical and not cost-efficient in clinical practice
to perform multiple predictive tests from the same tumor, but
examination of the extent of heterogeneity from a single sample
may help to guide treatment decisions [34]. It is also possible, that
even multiple tests would not detect a small tumor cell population
playing an important role in the further development of the drug
resistant tumor. A further possibility to elucidate the clonal
composition of the tumor is to examine the geno- and phenotype
of circulating tumor cells [35]. The better characterization of
tumor heterogeneity will be vital to increase the efficacy of
personalized treatment.
Finally, we must note a limitation of our cell line models, i.e.
they do not represent the tumor completely as they do not take
into consideration the interactions between the tumor epithelial
cells and the tumor microenvironment. Meanwhile, the tumor
microenvironment has been shown to be an important player in
response/resistance to chemotherapy [36]. Developing resistant
derivatives for example in nude mice could improve the model
efficiency.
In summary, we aimed to model in vitro the emergence of drug
resistance in cancer and were able to distinguish several previously
clinically validated predictors. In contrast to our expectations
chemoresistance evolution can emerge by only a limited number
of independent mechanisms.
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